Yes, I think that's a critical distinction, because on the plant biotech side, that has served us well. It wasn't the fact that it was a GMO that it needed to be regulated, it was the fact that you created a herbicide-tolerant crop. That was the novelty of what was being created, and that's why we needed to regulate it, so it has served us well in the whole GMO debate and discussion.
Now that we get into this more refined approach, it raises some questions in terms that you could have even that one-letter change creating a very novel crop, but does it still need to have the same A to Z regulatory review with the same data requirements?
That's the nuance, and that's the discussion we're having with officials at CFIA, that we think there are different tiers of approaches to take with these gene-edited products, everything from a full assessment, just like a biotech crop with foreign DNA, right down to either no regulation at all to different layers in between. I think even that would be a great improvement, because then we would know what those tiers are, and again, it would provide that predictability, and we would know approximately the time required for each of those levels.
Those are the more detailed discussions that we are having with officials and that we would like support on.